Literature DB >> 35693411

Pan-peroxisome proliferator-activated receptor agonist lanifibranor as a dominant candidate pharmacological therapy for nonalcoholic fatty liver disease.

Masato Yoneda1, Takashi Kobayashi1, Nogami Asako1, Michihiro Iwaki1, Satoru Saito1, Atsushi Nakajima1.   

Abstract

Entities:  

Year:  2022        PMID： 35693411      PMCID： PMC9186183          DOI： 10.21037/hbsn-21-579

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   8.265


× No keyword cloud information.
  13 in total

Review 1.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

2.  Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages☆.

Authors:  Sander Lefere; Tobias Puengel; Jana Hundertmark; Christian Penners; Anna Katharina Frank; Adrien Guillot; Kevin de Muynck; Felix Heymann; Vanessa Adarbes; Evelyne Defrêne; Céline Estivalet; Anja Geerts; Lindsey Devisscher; Guillaume Wettstein; Frank Tacke
Journal:  J Hepatol       Date:  2020-04-29       Impact factor: 25.083

3.  Why do so many NASH trials fail?

Authors:  Vlad Ratziu; Scott L Friedman
Journal:  Gastroenterology       Date:  2020-05-18       Impact factor: 22.682

4.  Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.

Authors:  Vlad Ratziu; Stephen A Harrison; Sven Francque; Pierre Bedossa; Philippe Lehert; Lawrence Serfaty; Manuel Romero-Gomez; Jérôme Boursier; Manal Abdelmalek; Steve Caldwell; Joost Drenth; Quentin M Anstee; Dean Hum; Remy Hanf; Alice Roudot; Sophie Megnien; Bart Staels; Arun Sanyal
Journal:  Gastroenterology       Date:  2016-02-11       Impact factor: 22.682

5.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

Authors:  Renata Belfort; Stephen A Harrison; Kenneth Brown; Celia Darland; Joan Finch; Jean Hardies; Bogdan Balas; Amalia Gastaldelli; Fermin Tio; Joseph Pulcini; Rachele Berria; Jennie Z Ma; Sunil Dwivedi; Russell Havranek; Chris Fincke; Ralph DeFronzo; George A Bannayan; Steven Schenker; Kenneth Cusi
Journal:  N Engl J Med       Date:  2006-11-30       Impact factor: 91.245

6.  A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.

Authors:  Sven M Francque; Pierre Bedossa; Vlad Ratziu; Quentin M Anstee; Elisabetta Bugianesi; Arun J Sanyal; Rohit Loomba; Stephen A Harrison; Rozalina Balabanska; Lyudmila Mateva; Nicolas Lanthier; Naim Alkhouri; Christophe Moreno; Jörn M Schattenberg; Diana Stefanova-Petrova; Luisa Vonghia; Régine Rouzier; Maeva Guillaume; Alexander Hodge; Manuel Romero-Gómez; Philippe Huot-Marchand; Martine Baudin; Marie-Paule Richard; Jean-Louis Abitbol; Pierre Broqua; Jean-Louis Junien; Manal F Abdelmalek
Journal:  N Engl J Med       Date:  2021-10-21       Impact factor: 91.245

7.  Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease.

Authors:  Atsushi Nakajima; Yuichiro Eguchi; Masato Yoneda; Kento Imajo; Nobuharu Tamaki; Hideki Suganami; Toshiaki Nojima; Ryohei Tanigawa; Masakazu Iizuka; Yuki Iida; Rohit Loomba
Journal:  Aliment Pharmacol Ther       Date:  2021-09-16       Impact factor: 9.524

Review 8.  Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

Authors:  Zobair M Younossi; Aaron B Koenig; Dinan Abdelatif; Yousef Fazel; Linda Henry; Mark Wymer
Journal:  Hepatology       Date:  2016-02-22       Impact factor: 17.425

9.  Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis.

Authors:  Yasushi Honda; Takaomi Kessoku; Yuji Ogawa; Wataru Tomeno; Kento Imajo; Koji Fujita; Masato Yoneda; Toshiaki Takizawa; Satoru Saito; Yoji Nagashima; Atsushi Nakajima
Journal:  Sci Rep       Date:  2017-02-14       Impact factor: 4.379

Review 10.  Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.

Authors:  Katsutoshi Tokushige; Kenichi Ikejima; Masafumi Ono; Yuichiro Eguchi; Yoshihiro Kamada; Yoshito Itoh; Norio Akuta; Masato Yoneda; Motoh Iwasa; Masashi Yoneda; Motoyuki Otsuka; Nobuharu Tamaki; Tomomi Kogiso; Hiroto Miwa; Kazuaki Chayama; Nobuyuki Enomoto; Tooru Shimosegawa; Tetsuo Takehara; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2021-09-17       Impact factor: 7.527
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.